glp-1 compound news FDA Intensifies Crackdown on Compounding Compounded GLP-1 Therapies: Access, Cost,

Indeed, despite only modest expression of the GLP-1 receptor in the kidney, the renoprotective actions of GLP-1 and its receptor agonists have become an area of intensive investigation

First-in-human phase 1 study of morab-202, an antibodydrug conjugate comprising farletuzumab linked to eribulin mesylate, in patients with folate receptor-positive advanced solid tumors

Researchers should expect attenuated rather than equivalent effects when extrapolating from preclinical data to human application

Together, they reduce melanin production, fade dark spots, and improve overall skin luminosity in a lightweight, non-greasy cream texture designed for daily morning and evening use